Evidence map›Paper›PMID 22380785›Full record

ArticleBMC infectious diseases2012

Marked variation in MSP-119 antibody responses to malaria in western Kenyan highlands.

Kingsley Badu, Yaw Asare Afrane, John Larbi, Virginia Ann Stewart, John Waitumbi, Evelina Angov, John M Ong'echa, Douglas J Perkins, Guofa Zhou, Andrew Githeko and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. eLife · 2021
    Pooled it
  2. Trial
  3. Serology reveals comparable patterns in the transmission intensities ofFrontiers in cellular and infection microbiology · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 3 countries.

Kingsley BaduCenter for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya. kingsleybadu@yahoo.com
Yaw Asare Afrane
John Larbi
Virginia Ann Stewart
John Waitumbi
Evelina Angov
John M Ong'echa
Douglas J Perkins
Guofa Zhou
Andrew Githeko
Guiyun Yan
Kenya Medical Research Institute · KEUnited States Army Medical Research Directorate - Africa · KEUniversity of California, Irvine · USCenter for Global Health · USKwame Nkrumah University of Science and Technology · GHUniversity of New Mexico · USWalter Reed Army Institute of Research · US

Funding

Research Training in Mosquito Genomics and Bioinformat*D43TW001505 · FIC · UNIVERSITY OF CALIFORNIA-IRVINE · PI Guiyun Yan · 2000 to 2026
$6.0M
TRAINING AND RESEARCH ON SEVERE MALARIAL ANEMIAD43TW005884 · FIC · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Collins Ouma, Douglas Jay Perkins · 2002 to 2026
$5.2M
FIC NIH HHS D43 TW001505FIC NIH HHS D43 TW005884PHS HHS R01 A1050243
6 · The paper itself

Abstract

backgroundAssessment of malaria endemicity at different altitudes and transmission intensities, in the era of dwindling vector densities in the highlands, will provide valuable information for malaria control and surveillance. Measurement of serum anti-malarial antibodies is a useful marker of malaria exposure that indicates long-term transmission potential. We studied the serologic evidence of malaria endemicity at two highland sites along a transmission intensity cline. An improved understanding of the micro-geographic variation in malaria exposure in the highland ecosystems will be relevant in planning effective malaria control.

methodsTotal IgG levels to Plasmodium falciparum MSP-119 were measured in an age-stratified cohort (< 5, 5-14 and ≥ 15 years) in 795 participants from an uphill and valley bottom residents during low and high malaria transmission seasons. Antibody prevalence and level was compared between different localities. Regression analysis was performed to examine the association between antibody prevalence and parasite prevalence. Age-specific MSP-119 seroprevalence data was fitted to a simple reversible catalytic model to investigate the relationship between parasite exposure and age.

resultsHigher MSP-119 seroprevalence and density were observed in the valley residents than in the uphill dwellers. Adults (> 15 years) recorded high and stable immune response in spite of changing seasons. Lower responses were observed in children (≤ 15 years), which, fluctuated with changing seasons particularly in the valley residents. In the uphill population, annual seroconversion rate (SCR) was 8.3% and reversion rate was 3.0%, with seroprevalence reaching a plateau of 73.3% by age of 20. Contrary, in the valley bottom population, the annual SCR was 35.8% and the annual seroreversion rate was 3.5%, and seroprevalence in the population had reached 91.2% by age 10.

conclusionThe study reveals the micro-geographic variation in malaria endemicity in the highland eco-system; this validates the usefulness of sero-epidemiological tools in assessing malaria endemicity in the era of decreasing sensitivity of conventional tools.

Indexed as

AdolescentAdultAnimalsAntibodies, ProtozoanChildChild, PreschoolCohort StudiesCross-Sectional StudiesEndemic DiseasesFemaleGeographyHumansImmunoglobulin GInfantKenyaMalaria, FalciparumAntibodies, ProtozoanImmunoglobulin GMerozoite Surface Protein 1

Identifiers

PMID22380785
PMCPMC3306741
OpenAlexW2125074245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.